Abstract

Sir Greg Winter is a pioneer of therapeutic monoclonal antibodies. Working at the MRC Laboratory of Molecular Biology, he developed the technology to ‘humanize’ mouse monoclonal antibodies, and subsequently to make fully human antibodies by phage display. One of the most successful academic entrepreneurs in Britain, Sir Greg founded the biotech companies Cambridge Antibody Technology (1989), Domantis (2000) and Bicycle Therapeutics Limited, which have a combined worth of over £930 million. He developed the anti-TNFα antibody Humira, the best-selling drug in the world, used for the treatment of rheumatoid arthritis. For his achievements, Sir Greg has been awarded the Royal Medal, the Louis Jeantet Prize for Medicine, and the Canada Gairdner International Award. He is a Fellow of the Royal Society and Master of Trinity College.

In recent years we have seen the emergence of a wave of new pharmaceuticals based on antibodies. Sir Greg Winter will describe the development of the field and where it is heading.

Everyone is welcome. Free for members, £2 on the door for non-members. Followed by refreshments (that means smoothies, cheese and grapes!).